Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)

NCT03648554 on ClinicalTrials.gov · last registry update 2019-06-25

93 participants. Its estimated completion date, 30 September 2023, has passed with no update to the record. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. dulaglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: UNKNOWN
Phase: P4
Drug: dulaglutide
Trulicity
Sponsor: Central Hospital, Nancy, France
Sponsor type: Other
Enrollment: 93
Started: 2019-09-01
Primary completion: 2023-09-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Responder's proportion difference between the two groups (dulaglutide (TRULICITY®) on top of dietary reinforcement vs. dietary reinforcement alone)

Conditions studied

Diabetes Mellitus, Type 2 · NASH - Nonalcoholic Steatohepatitis

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.